In vitro diagnostics (IVD) play a vital role in primary care and in diagnosing and treating cancer, cardiac dysfunction, and infectious diseases (such as HIV/AIDS, TB, malaria, coronavirus, etc.). IVDs are more crucial than ever for early detection, treatment decisions, and health outcomes. However, limited diagnostic capacity in resource-poor settings remains a significant obstacle to achieving treatment goals. Now, a groundbreaking technology has the potential to vastly expand access to IVD worldwide.

Most existing point-of-care (POC) diagnostic technologies follow a "one test, one patient" model. These POC IVDs are designed to perform a single test and can only analyze one sample at a time, making them too expensive and unaffordable for the people and communities that need them most. B-Matrix, an innovative immunoassay diagnostics platform from Picodya Technologies (Rehovot, Israel), is revolutionizing POC diagnostics on every front.

With just a few drops of blood, B-Matrix can conduct a panel of tests and analytes by generating thousands of picoliter (10-12) marker droplets, simultaneously performing a panel of tests and analyses for multiple patients. Results are available within minutes at an affordable cost per test that is at least one order of magnitude lower than existing POC solutions.

Compact and easy to use, B-Matrix is perfect for widespread deployment worldwide in medical centers, field hospitals, community clinics, research institutes, mass serological testing, home care, and more. This affordable, cost-effective unified technological platform enables a variety of test panels, making diagnostics more accessible to those who need it the most.

http://www.gzjiayumed.com/en/index.asp